Patients who administered at home had a higher rate of adherence (1.85 doses per patient per week) compared to administration at an infusion center (1.40 doses per week) or physicians office (1.40 doses per week). In addition, after the initiation of the training and support program, home administration increased by 61 percent, and an increase was seen across all age groups.
"Our goal at ViroPharma is to ensure that every patient who is prescribed Cinryze for routine prevention of HAE gets the support they need to optimize their experience," commented Paul Firuta, ViroPharma's vice president and general manager, Americas. "This includes product and disease educational materials as well as self administration training and support through our Path to Independence program."
ViroPharma helps patients find their own path by offering the Path to Independence Program, which provides hands-on self-administration training and on-going support from specially trained infusion nurses to appropriate people who are receiving therapy with Cinryze. To learn more about the Path to Independence™ Program visit http://www.cinryze.com/hae-patient-independence.aspx.
About Cinryze ® (C1 esterase inhibitor [human])Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product. In the U.S., Cinryze is approved by the FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In the E.U., the product is approved by the EMA for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. Cinryze is for intravenous use only. Severe hypersensitivity reactions to Cinryze may occur. Thrombotic events have occurred in patients receiving Cinryze, and in patients receiving off-label high dose C1 inhibitor therapy. Monitor patients with known risk factors for thrombotic events. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV